Education
About Us
Working with TipRanks
Follow Us
Passage Bio (PASG)
NASDAQ:PASG
PASG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.45 - $1.79
Previous CloseN/A
Volume182.24K
Average Volume (3M)141.31K
Market Cap
$32.00M
Enterprise Value-$15.77M
Total Cash (Recent Filing)$36.77M
Total Debt (Recent Filing)$26.48M
Price to Earnings (P/E)―
Beta1.59
Next Earnings
May 19, 2025EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.17
Shares Outstanding61,767,284
10 Day Avg. Volume121,685
30 Day Avg. Volume141,310
Standard Deviation0.25
R-Squared0.10
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)55.64
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.49
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.24
Enterprise Value/Ebitda0.24
Forecast
1Y Price Target
$4.00Price Target Upside669.23% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Passage Bio News
PremiumCompany Announcements
Passage Bio Reports 2024 Financial Results and Program Advances
PremiumCompany Announcements
Passage Bio Restructures and Extends Cash Runway
PremiumCompany Announcements
Passage Bio Shows Progress in Gene Therapy Trials
PremiumCompany Announcements
Passage Bio Achieves Milestones in Gene Therapy Trials---
Bulls Say, Bears Say
Bulls Say
Clinical ProgressInterim clinical data from Cohort 1 in the upliFT-D trial continue to be encouraging, with patient dosing underway in Cohort 2.
Regulatory SupportFDA should be supportive of an accelerated approval pathway given the devastating nature of FTD with no treatments available.
Bears Say
Safety ConcernsThe first patient dosed in cohort 1 discontinued treatment last year after immune response to treatment caused 2 SAEs (hepatoxicity and venous sinus thrombosis).
---
Ownership Overview
26.55% Insiders
4.94% Mutual Funds
<0.01% Other Institutional Investors
65.10% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PASG FAQ
What was Passage Bio’s price range in the past 12 months?
Passage Bio lowest stock price was $0.45 and its highest was $1.79 in the past 12 months.
What is Passage Bio’s market cap?
Passage Bio’s market cap is $32.00M.
When is Passage Bio’s upcoming earnings report date?
Passage Bio’s upcoming earnings report date is May 19, 2025 which is in 76 days.
How were Passage Bio’s earnings last quarter?
Currently, no data Available
Is Passage Bio overvalued?
According to Wall Street analysts Passage Bio’s price is currently Undervalued.
Does Passage Bio pay dividends?
Passage Bio does not currently pay dividends.
What is Passage Bio’s EPS estimate?
Passage Bio’s EPS estimate is -0.22.
How many shares outstanding does Passage Bio have?
Passage Bio has 61,767,284 shares outstanding.
What happened to Passage Bio’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Passage Bio?
Currently, no hedge funds are holding shares in PASG
---
Passage Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (669.23% Upside)
$4.00 (669.23% Upside)
Blogger Sentiment
Bullish
PASG Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $273.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 2.0%
Last 30 Days ▲ 2.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.05%
12-Months-Change
Fundamentals
Return on Equity
-69.15%
Trailing 12-Months
Asset Growth
-33.97%
Trailing 12-Months
Company Description
Passage Bio
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
---
PASG Stock 12 Month Forecast
Average Price Target
$4.00
▲(669.23% Upside)
Technical Analysis
Fate Therapeutics
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering PASG
1 Year
1 Year Success Rate
3/13 ratings generated profit
1 Year Average Return
-27.00%
reiterated a buy rating 4 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 23.08% of your transactions generating a profit, with an average return of -27.00% per trade.
---